Document is current
Any future updates will be listed below
-
Authors
Qiao, Zeyu https://orcid.org/0000-0003-2810-9748
Nguyen, Long C. https://orcid.org/0000-0002-4637-2331
Yang, Dongbo https://orcid.org/0000-0002-8343-5477
Dann, Christopher
Thomas, Deborah M. https://orcid.org/0000-0003-1599-264X
Henn, Madeline
Valdespino, Andrea
Swenson, Colin S. https://orcid.org/0000-0002-4883-8684
Oakes, Scott A. https://orcid.org/0000-0003-2099-2249
Rosner, Marsha Rich https://orcid.org/0000-0001-6586-8335
Moellering, Raymond E. https://orcid.org/0000-0002-2043-7838
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01EY027810; R01CA219815; R01CA266643;, DP2GM128199; R01GM145852; F32GM148062)
American Cancer Society (RSG-17-150-01-CDD)
U.S. Department of Defense (W81XWH2110120)
V Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 3 November 2023
Accepted: 1 August 2024
First Online: 30 August 2024
Competing interests
: Z.Q., L.C.N., C.S.S., S.A.O., M.R.R. and R.E.M. are listed as inventors on patent (PCT/US22/80387) applications related to this study. S.A.O. is a cofounder, equity holder and consultant for OptiKIRA, LLC. R.E.M. is a cofounder and consultant for Anastasis Biotec, Ltd. and cofounder, director and consultant for ReAx Biotechnologies, Inc. All other authors declare no competing interests.
